Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
This Month's Exclusive Article
Insider Trades: Okta and Abbott See Buys, Micron Insiders SellSubmitted by Leo Miller. Article Published: 5/13/2026. 
Key Points
- Interesting insider trades have recently hit three key stocks experiencing very different near-term performance.
- Insiders are purchasing shares of cybersecurity stock Okta, and healthcare giant Abbott.
- Meanwhile, after a historically strong run, Micron's insider selling has increased in Q2.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Insiders are making moves in three stocks that have seen major shifts in value over the recent past. That includes insiders buying shares in names that have fallen more than 30% and sales in one of the market’s hottest tech stocks. Here are the signals insiders are sending to investors in Q2. As AI Fears Weigh on Okta, an Insider Steps InFirst up is Okta (NASDAQ: OKTA), a stock that has struggled considerably. Compared with its 52-week high, Okta is down nearly 40%. One of the main drivers is concern about the effect artificial intelligence (AI) may have on the cybersecurity sector.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
The market is running scared on the idea that AI models will solve many of the problems cybersecurity companies have built businesses around. However, there is also an argument that, in the wrong hands, AI models increase cyber risk, potentially making these companies more important than ever. Amid Okta’s struggles, one insider is clearly showing confidence in the business. In Q2, Director David Schellhase purchased around $267,000 worth of Okta stock, a bullish signal. Still, investors will notice that insider sales in Q2 have considerably outweighed his purchase, at $1.2 million. However, the details are interesting. The sales and purchases both came under predetermined 10b5-1 plans. When it comes to 10b5-1 sales, the negative signal they send is somewhat limited, as they are often simply used by insiders to gain liquidity over long periods. On the other hand, insiders tend to buy their company’s stock only if they think the price will rise. So 10b5-1 plan buys are still bullish, and potentially even more so than non-10b5-1 buys. They signal sustained conviction, as future purchases through this plan are likely to occur. Micron’s Insider Selling: Red Flag or Non-Issue?Micron Technology (NASDAQ: MU) was one of the market's best-performing stocks in 2025 and has continued to move higher rapidly in 2026. After notching a 240% gain in 2025, shares have already risen more than 170% so far in 2026. The reason for Micron’s rise is well documented: memory chips are in short supply, while demand from AI data centers is intense. These dynamics have led Micron to post some astonishing financial metrics. In its latest quarter, Micron’s revenue rose 196% year over year (YOY) to a record $23.9 billion. Meanwhile, earnings per share rose 682% YOY to $12.20. However, the company is also seeing some notable insider activity in Q2. Insider sales have approximately doubled from Q1, rising to $45 million versus $22 million last quarter. The company has also not seen any insider buys, compared with $7.8 million in buys during Q1. Still, the majority, or $35 million, of these sales came under a 10b5-1 plan. Sumit Sadana’s $10.1 million sale did not. However, Sadana’s sale was a moderate trim rather than an exit, representing around 10% of his holdings. Overall, while not positive, the mitigating factors make Micron’s recent sales not overly concerning. Abbott Insiders Send Bullish Signals as Shares Plummet in 2026Last up is Abbott Laboratories (NYSE: ABT), one of the world’s largest names in healthcare equipment and supplies. Abbott is another company experiencing weakness, down more than 20% since the start of 2025 and down over 30% in 2026. Abbott’s recent earnings reports were major contributors to the stock’s decline. In Q4 2025, Abbott posted mixed results, with adjusted earnings per share (EPS) in line at $1.50 but revenue that fell short of expectations by $342 million. The company’s guidance for 2026 was essentially in line with estimates. However, markets focused on the miss, pushing Abbott shares down 10% in response. Its Q1 2026 results saw top- and bottom-line beats, but Abbott lowered its full-year EPS guidance, sending shares down 6%. However, multiple insiders are picking up the slack in this stock, with total insider purchases of $1.13 million in Q2. This adds to buying in Q1, which came in at $1.09 million, and MarketBeat has tracked no insider sales in Q2 thus far. The uptick in purchases clearly coincides with Abbott’s significant 2026 decline, which has been a drag on longer-term performance. This suggests insiders are buying what they likely see as a dip in Abbott stock, a positive sign going forward. Analysts Eye Solid Upside in Abbott Amid 2026 SlideTrades surrounding Micron do not send a strong signal. However, buys at Okta and Abbott are worth noting. Importantly, investors should remember that insider transactions are just one tool for assessing the future of individual stocks. They are not declarations of how these names will move going forward. Still, Wall Street analysts are echoing the sentiment of insiders when it comes to Abbott. The MarketBeat consensus price target on shares near $119 implies more than 40% upside in the stock. Targets updated after the company’s latest earnings report are similarly bullish. The average of these targets is only slightly lower than the consensus, at approximately $118. |
No comments:
Post a Comment